The ability to predict progression to severe AKI remains an unmet challenge. Early prognostic biomarkers of AKI hold promise to improve patient outcomes by early implementation of clinical therapy, as well as unravel the pathophysiological mechanisms of AKI. Here, we present a novel urinary biomarker, IGFBP-1, that predicts the progression to severe AKI following cardiac surgery. In addition, we show that IGFBP-1 mice are protected against CIAKI, suggesting a mechanistic role for IGFBP-1 in AKI.
Diabetic kidney disease (DKD) is the most common cause of chronic kidney disease (CKD) and kidney failure in addition to determining an elevated risk of cardiovascular (CV) disease. Traditional approaches to DKD management have focused primarily on slowing kidney disease progression through improved glycemic control. However, growing recognition of the complex interplay among metabolic, kidney, and CV dysfunction has led to the emergence of the cardio-kidney-metabolic (CKM) syndrome framework, emphasizing the interconnected pathophysiology and shared risk profiles of these conditions. This evolving paradigm has transformed the understanding and management of DKD from an isolated kidney disorder to a multisystem disease requiring integrated therapeutic strategies. Recent advances have significantly altered the landscape of DKD management. In addition to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, newer therapies including sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists have demonstrated substantial kidney and CV protective effects. Emerging evidence suggests that combination therapy may potentially shift the treatment paradigm from slowing CKD progression toward preservation of kidney function. In this review, we discuss DKD within the broader framework of CKM syndrome, highlighting the epidemiologic, pathophysiologic, prognostic, and therapeutic intersections among diabetes, CKD, and CV disease. We summarize major therapeutic advances, review evidence supporting multidrug combination strategies, and examine current gaps between clinical evidence and real-world implementation. We further propose a phenotype-driven framework for sequencing combination therapy based on each patient’s dominant pathophysiologic driver as a hypothesis-generating alternative to uniform add-on strategies. Finally, we discuss the future direction of DKD management and the need for integrated multidisciplinary approaches aimed at improving outcomes.
Diabetic kidney disease (DKD) represents the single most common etiology of chronic kidney disease and end stage kidney disease globally, a burden that continues to expand in direct proportion to the worldwide growth of the diabetes epidemic. The pathogenesis of DKD is multifactorial, involving metabolic, hemodynamic, inflammatory, and fibrotic pathways. Among these, aldosterone has emerged as a key mediator of kidney injury, extending beyond its traditional role in sodium balance and blood pressure regulation. Through activation of both MR-dependent transcriptional processes and MR-independent signaling cascades, aldosterone drives a coordinated pattern of renal injury encompassing oxidative stress generation, endothelial dysfunction, podocyte damage, inflammatory cell recruitment, and progressive interstitial fibrosis. Current therapies targeting the renin–angiotensin–aldosterone system (RAAS), including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists, have significantly improved outcomes in DKD. Despite these advances, a considerable degree of residual cardiovascular and renal risk persists, attributable in part to the incomplete attenuation of aldosterone activity and the well-characterized phenomenon of aldosterone escape under sustained RAAS blockade. Aldosterone synthase inhibitors (ASIs) represent a mechanistically distinct therapeutic approach that targets aldosterone overproduction at its enzymatic source, potentially addressing both MR-dependent and independent pathways. Early clinical trials evaluating the efficacy of ASIs have demonstrated promising effects on blood pressure and albuminuria. This review summarizes the role of aldosterone in DKD pathogenesis, evaluates current therapeutic approaches, and discusses emerging evidence supporting ASIs as a potential addition to the evolving treatment landscape.